Effect of PTPRδ rs17584499 C/T Polymorphism on Therapeutic Efficacy of Metformin in Bangladeshi Patients with Type 2 Diabetes

Abstract

Type 2 diabetes mellitus (T2DM) is a polygenic and complex disorder that is difficult to treat effectively in the long term without oral anti-diabetic agents. Genetic variants of these susceptible genes provided the new targets for prevention, diagnosis and treatment of T2DM. Metformin is the first-line agent for T2DM patients that reduces gluconeogenesis by increasing hepatic sensitivity to insulin. To investigate the effect of the rs17584499 C/T polymorphism on metformin therapeutic efficacy in BangladeshiT2DM patients, a fragment of 540 bp of protein tyrosine receptor type delta (PTPRδ) was analysed in 50 T2DM patients having only metformin and 25 healthy controls. In this study it was revealed that T2DM patients having only metformin to treat their disease for 3.62±2.97 years managed their glucose level and lipid profile to within the reference value. Two additional SNPs (rs1978741G/A and rs7865131C/G) within target SNP rs17584499 C/T were also identified. It was found that, the probability of the association of target rs17584499 C/T and newly identified rs1978741G/A with development of T2DM and their effect on metformin therapeutic effect on metformin in Bangladeshi T2DM patients is very low. But carriers of another newly identified rs7865131C/G: the G allele might be having higher susceptibility to T2DM as well as might have adverse effect on therapeutic effect on metformin in patients with T2DM.